Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Saved in:
| Title: | Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. |
|---|---|
| Authors: | Llombart-Cussac A; Hospital Arnau de Vilanova, FISABIO, Valencia, Spain. antoniollombart@medsir.org.; Universidad Católica de Valencia, Valencia, Spain. antoniollombart@medsir.org.; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. antoniollombart@medsir.org., Prat A; Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.; University of Barcelona, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors Lab., Barcelona, Spain., Pérez-García JM; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain.; International Breast Cancer Center, Pangea Oncology, QuironSalud Group, Barcelona, Spain., Mateos J; IEC Barcelona, Barcelona, Spain., Pascual T; Hospital Clínic i Provincial de Barcelona, Barcelona, Spain., Escrivà-de-Romani S; Hospital Universitari Vall Hebrón. Vall d'Hebron Institute of Oncology, Barcelona, Spain., Stradella A; ICO L'Hospitalet, Barcelona, Spain., Ruiz-Borrego M; Hospital Virgen del Rocío, Seville, Spain., de Las Heras BB; HCU Valencia, INCLIVA, Universidad de Valencia (CIBERONC-ISCIII, Madrid), Valencia, Spain., Keyaerts M; Vrije Universiteit Brussel, Brussels, Belgium., Galvan P; Translational Genomics and Targeted Therapies in Solid Tumors Lab., Barcelona, Spain., Brasó-Maristany F; Translational Genomics and Targeted Therapies in Solid Tumors Lab., Barcelona, Spain., García-Mosquera JJ; Dr. Rosell Oncology Institute (IOR), Dexeus University Hospital, Pangaea Oncology, Quironsalud Group, Barcelona, Spain., Guiot T; Université Libre de Bruxelles, Hôpital Universitaire de Bruxelles, Institute Jules Bordet, Brussels, Belgium., Gion M; Hospital Ramón y Cajal, Madrid, Spain., Sampayo-Cordero M; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain., Di Cosimo S; Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Pérez-Escuredo J; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain., de Frutos MA; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain., Cortés J; Universidad Católica de Valencia, Valencia, Spain.; International Breast Cancer Center, Pangea Oncology, QuironSalud Group, Barcelona, Spain.; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain., Gebhart G; Université Libre de Bruxelles, Hôpital Universitaire de Bruxelles, Institute Jules Bordet, Brussels, Belgium. |
| Source: | European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Jul; Vol. 51 (9), pp. 2733-2743. Date of Electronic Publication: 2024 Apr 08. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1619-7089 (Electronic) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1619-7089 |
|---|---|
| DOI: | 10.1007/s00259-024-06683-0 |
